KKR, Assura, and the £1.56 Billion Dance: A Lesson in Bids, and Bold Moves

Welcome to the world of corporate finance – where billion-pound bids and strategic calculations drive the biggest decisions. Stepping on to the dance floor, KKR, American private equity powerhouse, and Assura, the UK healthcare property developer, in what can only be described as a financial tango that’s got everyone talking.

So, what’s the fuss about? And why is KKR eyeing Assura with the intensity of a strategist spotting a prime opportunity? Let’s get to the heart of this corporate pursuit.

What Happened?

Here’s the scoop: KKR turned up with a cheque for £1.56 billion – a substantial sum to acquire Assura. They offered 48 pence per share, which was 28% above Assura’s recent share price. Generous, right? Well, not according to Assura’s board, who rejected the offer faster than you can say “net asset value.”

Assura believes the bid undervalues the company, given their portfolio of NHS-backed medical centres. The rejection sent Assura’s share price up 9.1% to 42.5 pence, but KKR now has until March 14th to decide if they want to up the ante or walk away.

Who Are These Companies?

• Assura plc: The UK’s healthcare property landlord, owning GP surgeries and community medical centres across our green and pleasant land. Their properties are leased to NHS-backed tenants, making their rental income as reliable as a British queue.
• KKR (Kohlberg Kravis Roberts & Co.): The US private equity giant famous for leveraged buyouts – including the infamous RJR Nabisco deal of Barbarians at the Gate fame. If there’s an undervalued asset up for grabs, KKR probably has it earmarked.

What’s a Bid Anyway?

A bid in M&A terms is when one company offers to buy another, usually at a premium to entice shareholders. KKR’s 48p-per-share bid was public and straightforward: “We’ll buy your company for more than it’s currently worth.” The board, however, saw the bid as more of a lowball offer than a fair valuation.

Now KKR has two choices: raise the bid or walk away. And if they really want it, there’s always the nuclear option – a hostile takeover, where they bypass the board and go directly to shareholders. Bold, but risky.

Why Does KKR Want Assura?

• Steady, Government-Backed Cash Flows: NHS leases mean predictable income – no rent defaults here unless the government decides to ghost its GP surgeries.
• Healthcare Growth: An ageing population and increased demand for community healthcare make this sector a hot ticket.
• Asset Bargain: Assura’s shares have been trading below their net asset value (NAV), so KKR sees a potential steal.
• Diversification: KKR loves infrastructure-like investments, and healthcare fits the bill.

How Does KKR Pay for This?

KKR doesn’t just whip out a chequebook. Here’s their likely playbook:

1. Private Equity Funds: KKR manages multi-billion-pound funds filled with money from pension funds, insurers, and institutions.
2. Debt Financing (LBOs): The classic KKR move – borrowing a significant chunk of the purchase price, secured against Assura’s assets.
3. Co-Investors: USS (the Universities Superannuation Scheme) was initially interested but dropped out. KKR might find another pension fund to join the party.
4. Asset Sales: Sell off mature investments to free up cash.
5. SPVs (Special Purpose Vehicles): A fancy way to say “let’s set up a company just for this deal.”

So, What Next?

KKR now has a month to decide whether to sweeten the deal or walk away. If they increase the offer, expect Assura’s board to huddle up once again. If KKR bows out, Assura might feel vindicated – or regret the missed opportunity.

Either way, it’s a masterclass in corporate courtship: big bids, big decisions, and the enduring allure of NHS-backed medical centres. Because in finance, as in life, it’s not just about what you offer – it’s about whether the other side believes you’re worth it.

Stay tuned. And maybe, just maybe, keep an eye on your assets when KKR’s around.